SJD Barcelona Children’s Hospital
SJD Barcelona Children’s Hospital
Spagna, Barcellona
Solo per bambini e adolescenti (0-18 anni)
Clinica certificata da :
| Turchia | Austria | Spagna | |
| Trattamento sintomatico | da $300 | da $700 | da $800 |
| Plasmaferesi | da $1,200 | da $2,000 | da $1,800 |
| Scambio di plasma | da $3,900 | - | - |
| Aferesi terapeutica | da $1,350 | - | - |
Dr. Francesc Cobo Valien is a leading oncohematologist at the Teknon Oncology Institute in Barcelona. He specializes in treating complex blood cancers, including leukemia and lymphoma. Dr. Cobo Valien earned his medical degree and doctorate from the University of Barcelona. He serves patients at Centro Médico Teknon, a JCI-accredited facility.
Il medico è specializzato in linfomi e leucemia linfatica cronica, guidando innovazioni nell'analisi e nel trattamento delle malattie ematologiche. Rinomato a livello globale per la sua esperienza nella Leucemia Linfatica Cronica (CLL), il medico conduce ricerche cliniche e di base significative, concentrandosi sulla patogenesi molecolare e nuovi approcci terapeutici.<\/p>
Attualmente coinvolto in oltre 80 studi dalla fase 1 alla fase 3, il medico contribuisce allo sviluppo di nuovi farmaci e trattamenti. Come Capo dell'Ematologia presso l'IOB Institute of Oncology e Capo del Dipartimento di Ematologia presso il Vall d’Hebron University Hospital, il medico ha pubblicato oltre 100 articoli su riviste prestigiose.<\/p>
Il medico è uno specialista esperto in ematologia oncologica pediatrica e un neurochirurgo pediatrico di spicco in Spagna. Con oltre 30 anni di esperienza pratica, il medico guida l'Unità di Ematologia e Oncologia Pediatrica presso HM Hospitales, concentrandosi su gravi malattie ematologiche e cancerose nei bambini e negli adolescenti.<\/p>
Il medico è specializzato nella diagnosi e nel trattamento dei disturbi ematologici e cancerosi, in particolare nei sistemi eritrocitario, mieloide e linfoide. Il medico serve come consulente per l'OMS e l'UNESCO ed è coinvolto in attività di insegnamento e ricerca.<\/p>
Le credenziali educative includono lauree presso l'Universidad Complutense de Madrid, l'Università di Barcellona e l'Università del Maryland.<\/p>
Il medico possiede una laurea in Medicina presso l'Università Complutense di Madrid e un dottorato presso l'Università di Barcellona. Specializzandosi in Ematologia e Oncologia Pediatrica presso l'Università del Maryland, il medico è esperto nel trattamento di tumori ossei e cerebrali, nonché di leucemia e malattie ematologiche.<\/p>
Con oltre due decenni di esperienza, il medico attualmente dirige l'Unità di Ematologia e Oncologia Pediatrica presso l'Ospedale HM Montepríncipe, concentrandosi sulla cura di bambini e adolescenti. In precedenza, il medico ha ricoperto la stessa posizione presso l'Ospedale Universitario Clínica San Rafael ed è autore di numerose pubblicazioni scientifiche.<\/p>
Spanish hematologists follow clinical guidelines established by the Spanish ITP Working Group (GEPTI). Treatment decisions depend on platelet counts and bleeding risks. Clinical protocols prioritize diagnostic exclusion to rule out secondary causes. Active intervention typically begins when platelet counts drop below 20 × 10⁹/L.
Bookimed Expert Insight: Spain’s hematological landscape is highly specialized, evidenced by Clinica Universidad de Navarra being the first to receive JCI accreditation in the country. Data shows that top centers like SJD Barcelona handle 450,000 patients annually. This high volume allows Spanish specialists to refine conservative `watchful waiting` protocols for counts above 20 × 10⁹/L, effectively reducing unnecessary steroid exposure for asymptomatic patients.
Patient Consensus: Patients note that doctors prioritize bleeding history over raw numbers and often request a series of past blood counts to identify trends. It is common to undergo observation without medication if symptoms are absent and counts remain stable.
Spanish hematologists typically start active treatment for primary immune thrombocytopenia (ITP) when platelet counts drop below 20,000/µL in asymptomatic adults. Patients over 65 years or those with high bleeding risks receive treatment at a threshold of 30,000/µL. Active bleeding triggers immediate intervention regardless of the count.
Bookimed Expert Insight: Spanish hematology centers like Clinica Universidad de Navarra maintain a high degree of specialization, being the first in Spain with JCI accreditation. Data analysis shows that while guidelines set thresholds, top specialists like Dr. Francesc Bosch focus on molecular pathogenesis to individualize care. This explains why clinics with over 140,000 annual patients prioritize multidisciplinary consultations before prescribing restricted 4-week corticosteroid courses.
Patient Consensus: Patients note that doctors in Spain often prefer a watch-and-wait approach if no symptoms appear. They emphasize reporting new bruising or nosebleeds immediately, as these signs often trigger treatment faster than the blood test numbers alone.
Spanish hospitals utilize European Medicines Agency approved medications and Spanish National Health System protocols. First-line treatments for thrombocytopenia prioritize corticosteroids like prednisone or dexamethasone. Critical care cases often require intraveinous immunoglobulin (IVIG) for rapid platelet stabilization. These treatments are delivered within JCI-accredited facilities.
Bookimed Expert Insight: Spanish hematology units like those at Clinica Universidad de Navarra maintain exceptional quality standards. Our data shows Spain ranks 6th globally for medical requests. This popularity stems from high-volume centers like SJD Barcelona Children's Hospital. That facility serves 450,000 patients yearly with 800 specialized doctors. Higher patient volumes typically correlate with more refined medication protocols and faster diagnostic accuracy.
Patient Consensus: Patients note that Spanish hematology teams take a careful, stepwise approach. They often prefer conservative observation or standard steroids before moving to more aggressive medication options.
Advanced thrombopoietin receptor agonists in Spain are classified as Hospital Use medicines. Patients must access these therapies through a hospital hematologist rather than retail pharmacies. These treatments are strictly second-line options for patients showing insufficient response to corticosteroids or intravenous immunoglobulins.
Bookimed Expert Insight: Spain ranks sixth globally in patient requests served through our platform, reflecting a highly structured healthcare system. Data shows that while centers like Clinica Universidad de Navarra hold multiple JCI certifications, access to specific TPO-RAs often depends on regional hospital formularies. Patients should prepare detailed clinical records of prior treatment failures to streamline the internal hospital approval process.
Patient Consensus: Patients note that getting these drugs depends heavily on hospital committee approvals and specific regional rules. Many emphasize the need for regular hospital visits for bloodwork and suggest using private hematology for faster initial consultations.
Barcelona and Madrid are the primary hubs for thrombocytopenia care in Spain. Leading facilities include Clinica Universidad de Navarra in Pamplona and SJD Barcelona Children’s Hospital. These centers offer advanced hematology units with Joint Commission International accreditation and specialized diagnostic labs for platelet disorders.
Bookimed Expert Insight: Choosing between Madrid and Barcelona often depends on patient age and case complexity. Clinica Universidad de Navarra serves over 700,000 international patients and leads in rare disorder research. Meanwhile, Dr. Francesc Cobo Valien at Centro Médico Teknon offers specific expertise in autoimmune pancytopenia cases.
Patient Consensus: Patients note that speed of hematology review is vital for platelet disorders. They recommend prioritizing large teaching hospitals in Madrid or Barcelona that provide 24/7 transfusion support.